Document is current
Any future updates will be listed below
-
Authors
Fregnani, Eduardo R. https://orcid.org/0000-0001-5196-7631
Epstein, Joel B.
Blijlevens, Nicole M. A.
Yarom, Noam
Villa, Alessandro
Raber-Durlacher, Judith E.
Gardner, Pamela J.
Shem, Dennis
Beaumont, Sophie
Bossi, Paolo
Elad, Sharon
-
Funding
Funding for this research was provided by:
Tel Aviv University
- License Information
-
More Information
Article History
Received: 8 June 2025
Accepted: 23 July 2025
First Online: 13 September 2025
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: E. Fregnani, N. Blijlevens, N. Yarom, and S. Elad reported no relevant financial or non-financial interests to disclose. A. Villa is a consultant for Merck, K Pharmaceuticals, Afyx Therapeutics, Amgen, and Lipella Pharmaceuticals. A. Villa is Associate Editor for Supportive Care in Cancer. J.E. Raber-Durlacher received in kind support from Thor Photomedicine Ltd. J.B. Epstein is a consultant for Rakuten, Sanotize Inc., Janssen, Neilsen Inc. J.B Epstein is Associate Editor-in-Chief for Supportive Care in Cancer. P. Bossi reported participation to advisory board or conference honoraria for Merck, Sanofi-Regeneron, Merck Sharp & Dohme, Daiichi-Sankyo, Glaxo Smith Kline, Angelini, Nestlè, Nutricia.
: The MASCC/ISOO OCSG Statements have been developed to facilitate expert-opinion-based management of oral complications of cancer and cancer therapy, where high-quality evidence is lacking. Clinicians should use their judgment when making treatment decisions for individual patients. Statement authors and the MASCC/ISOO do not guarantee or take responsibility for the clinical outcomes in individual patients.
